EUVIMEDEUVIMED entdecken
KommentarOpen Access

Evidence Against Routine Use of Glucagon for Prostate MRI

Steven C Eberhardt iD

Radiology: Imaging Cancer · 2023

DOI: 10.1148/rycan.230053 ↗

Kurz gefasst

Kommentar in der Zeitschrift Radiology: Imaging Cancer, 2023. Verfasst von Steven C Eberhardt. Beteiligte Einrichtung: From the Department of Radiology, University of New Mexico, MSC10 5530, 1 University of New Mexico, Albuquerque, NM 87131. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansGlucagonMagnetic Resonance Imaging

Substanzen

Glucagon

Autor:innen und Institutionen

  • From the Department of Radiology, University of New Mexico, MSC10 5530, 1 University of New Mexico, Albuquerque, NM 87131.

ORCID-Profile: Steven C Eberhardt

Zitieren

APA

Eberhardt, S. C. (2023). Evidence Against Routine Use of Glucagon for Prostate MRI. Radiology: Imaging Cancer. https://doi.org/10.1148/rycan.230053

Vancouver

Eberhardt SC. Evidence Against Routine Use of Glucagon for Prostate MRI. Radiology: Imaging Cancer. 2023. doi:10.1148/rycan.230053

BibTeX
@article{Eberhardt2023,
  author = {Eberhardt, Steven C},
  title = {Evidence Against Routine Use of Glucagon for Prostate MRI},
  journal = {Radiology: Imaging Cancer},
  year = {2023},
  doi = {10.1148/rycan.230053}
}
Kostenlos starten →